Brazil's Anvisa to certify domestic API production, boosting local pharma supply

Brazil's health regulator Anvisa will certify active pharmaceutical ingredients (APIs) manufactured domestically, with participation in public research programs as a selection criterion. This marks a policy shift toward reducing reliance on imported APIs, strengthening local pharmaceutical supply chains. The move could lower drug costs and improve health security, though implementation details remain unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works